Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Corynebacterium diphtheriae is a Gram-positive, non-motile, non-capsulated, club-shaped bacillus responsible for diphtheria, a serious infectious disease that primarily affects the mucous membranes of the respiratory tract or skin. Its pathogenicity is largely due to a potent exotoxin (diphtheria toxin) encoded by a bacteriophage-borne gene (tox). Toxigenic strains colonize the upper respiratory tract or skin, forming a pseudomembrane and releasing toxin systemically, which can lead to severe complications including myocarditis and neuropathy. Laboratory diagnosis relies on culture, toxin detection, and PCR-based identification. Infection is prevented with vaccination (diphtheria toxoid), and treated with antitoxin and antibiotics such as penicillin or erythromycin. Drug-resistant strains have emerged, highlighting ongoing challenges in management[1][3][4][5].
For antitoxin, neutralization of diphtheria toxin; for antibiotics, inhibition of bacterial cell wall synthesis (penicillin), inhibition of protein synthesis (erythromycin)[4]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corynebacterium diphtheriae.